Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

Recruiting Observational Study
Coronary Artery Disease Coronary Artery Bypass Graft (CABG)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
20 – 80
Sex
Any
Study type
Observational
Participants needed
15 (estimated)
Sponsor
University of Texas Southwestern Medical Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This prospective, non-blinded, single-center, translational research study aims to validate a multimodal advanced imaging exam for cardiac viability. The protocol utilizes three distinct imaging modalities: Single Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT MPI), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), and Hyperpolarized Carbon-13 (HP-13C) Pyruvat…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Study Population Description The study population will consist of 12 to 15 human subjects divided into two main groups. The first group includes 6 healthy individuals with a normal left ventricular ejection fraction (LVEF \> 0.50). The second group comprises 9 patients with advanced ischemic cardiom…
Contacts

Sarah McNeil, RN

214-645-7700

sarah.mcneil@utsouthwestern.edu

CONTACT

Cesia Rodriguez Gongora, RN

214/645-7739

cesia.rodriguezgongora@utsouthwestern.edu

CONTACT